Ember LifeSciences announces new strategic investments boosting Series A to $27M

Ember LifeSciences announced new strategic investments from Amgen Ventures, the corporate venture arm of Amgen (NASDAQ: AMGN), and TDF Ventures, raising total Series A funding to $27 million.

Rhea-AI Summary

Ember LifeSciences announced new strategic investments from Amgen Ventures, the corporate venture arm of Amgen (NASDAQ: AMGN), and TDF Ventures, raising total Series A funding to $27 million.

The financing coincides with full commercial availability of the Ember Cube 2, a reusable, modular cold chain shipping solution with real-time monitoring and cloud-based tracking. Ember’s platform targets costly temperature excursions in pharmaceutical logistics and builds on a customer base that includes CVS Health, Cardinal Health, Chartwell and USADA.

Positive

• Series A funding increased to $27 million
• New strategic investors Amgen Ventures and TDF Ventures
• Full commercial launch of Ember Cube 2 cold chain solution
• Product recognition from Red Dot, TIME and Fast Company

Negative

• None.

Argus May 27 session

+0.04% close to close 0.7x rel. volume Open Argus

Details

News Market Reaction – AMGN

On May 27, the day this news came out, AMGN closed 0.04% above the previous close.

Data tracked by StockTitan Argus for the May 27 session.

Key Figures

Series A funding: $27 million

Series A funding

$27 million

Total Ember LifeSciences Series A to date

Historical Context

5 past events · Latest: May 19

5 events

1. May 19

   CFO transition

   24h Move

   -0.3%

   Announced retirement of CFO and appointment of successor with transition timeline.

2. May 07

   Conference appearance

   24h Move

   +0.8%

   Planned presentation at a major healthcare conference with webcast access details.

3. May 04

   Capex expansion

   24h Move

   -1.8%

   Announced additional $300M U.S. manufacturing investment, lifting total to nearly $2B.

4. Apr 30

   Earnings correction

   24h Move

   -4.8%

   Provided corrected Q1 2026 figures and reiterated revenue and EPS guidance ranges.

5. Apr 30

   Q1 2026 earnings

   24h Move

   -4.8%

   Reported Q1 revenue growth, EPS increases, margin expansion and full-year guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cold chain, temperature-controlled distribution, cloud-based tracking

3 terms

cold chain technical

"a leading provider of revolutionary cold chain technology, today announced"

A cold chain is the continuous temperature-controlled system used to store and transport products that must stay cold, such as vaccines, biologic medicines, and some foods — think of a refrigerator on wheels and in warehouses that keeps items at specific temperatures from factory to customer. Investors watch cold chain strength because failures raise product loss, regulatory trouble, and extra costs, while reliable cold chains protect sales, margins, and a company’s reputation.

temperature-controlled distribution technical

"as more medicines and vaccines require temperature-controlled distribution."

Temperature-controlled distribution is the system of transporting and storing products while keeping them within specific temperature ranges to preserve quality and safety, like keeping dairy chilled from farm to table. For investors it matters because maintaining those conditions requires specialized equipment, procedures and regulatory compliance, which affect costs, risk of product loss, market access and a company’s reputation if shipments fail or spoil.

cloud-based tracking technical

"through real-time monitoring and cloud-based tracking."

Cloud-based tracking is using remote servers and internet software to collect, store and analyze real-time data about products, customers, shipments, or digital usage instead of keeping records on local computers. For investors, it matters because it can lower IT costs, speed decision-making, and scale operations quickly—like swapping a personal filing cabinet for a flexible online assistant that updates and reports automatically—affecting revenue growth, margins and risk exposure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ANGELES, May 27, 2026 /PRNewswire/ -- Ember LifeSciences, Inc., ("Ember") a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen Ventures, the corporate venture arm of Amgen (NASDAQ: AMGN) a leading global biotechnology company and TDF Ventures, a venture capital firm focused on early-stage investments in enterprise-focused technology sectors.

The investments follow Ember LifeSciences' previously announced Series A financing led by Sea Court Capital and comes as the company announces full commercial availability of the Ember Cube 2, an award-winning, reusable, modular solution designed to bring greater control and visibility to cold chain logistics through real-time monitoring and cloud-based tracking.

"Investments from Amgen and TDF Ventures provide us with the deep industry insights needed to scale our logistics platform rapidly," said Clay Alexander, founder and CEO of Ember LifeSciences. "Their investments mark a turning point as we expand our global footprint and bring a new level of precision to healthcare delivery."

The pharmaceutical cold chain faces billions of dollars in annual losses due to temperature excursions, a problem that the industry is under more pressure to solve as more medicines and vaccines require temperature-controlled distribution. Ember aims to address these challenges through its reusable shipping platform. Its latest Ember Cube 2 was recently named "Best of the Best" by the Red Dot Award for product design.

Ember's existing customers and investors include leading pharmaceutical distributors and pharmacies including CVS Health, Cardinal Health, Chartwell and USADA. In addition to the Ember Cube 2, its product suite includes the flagship Ember Cube, which was named a 2024 TIME Magazine Invention of the Year and a 2024 Fast Company World Changing Idea. 

Financial terms of the new investments were not disclosed. The company's total Series A funding to date now stands at $27 million.

About Ember LifeSciences
Ember LifeSciences initially launched as an offshoot of Ember Technologies' "Ember," the design-led temperature control brand and maker of the award-winning temperature control mug, which has surpassed half a billion dollars in total sales to date. Ember LifeSciences seeks to redefine global medicine distribution through leveraging Ember's proprietary temperature control technology to improve the way we transport life-saving medicines and vaccines around the world. To learn more about Ember LifeSciences, visit emberlifesciences.com.

Media Contact
Meghan Bianco
609-544-5446
embermedia@rfbinder.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ember-lifesciences-announces-new-strategic-investments-boosting-series-a-to-27m-302783076.html

SOURCE Ember LifeSciences

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amgen Ventures invest in Ember LifeSciences and how does it relate to AMGN?

Amgen Ventures invested in Ember LifeSciences as a strategic backer, while Amgen remains listed as NASDAQ: AMGN. According to Ember LifeSciences, Amgen Ventures brings biotechnology industry insight to support scaling Ember’s cold chain logistics platform and expanding its global healthcare delivery footprint.

How much Series A funding has Ember LifeSciences raised as of May 27, 2026?

Ember LifeSciences has raised a total of $27 million in Series A funding. According to Ember LifeSciences, this includes earlier financing led by Sea Court Capital plus the latest investments from Amgen Ventures and TDF Ventures to support platform scaling and commercialization.

What is the Ember Cube 2 and why is it important for pharmaceutical logistics?

Ember Cube 2 is a reusable, modular shipping solution designed for temperature-controlled pharmaceutical logistics. According to Ember LifeSciences, it offers real-time monitoring and cloud-based tracking to improve control, reduce temperature excursions and enhance visibility across the pharmaceutical cold chain distribution network.

Which investors and customers support Ember LifeSciences’ cold chain platform?

Ember LifeSciences is backed by Amgen Ventures, TDF Ventures, Sea Court Capital and others. According to Ember LifeSciences, customers and investors include major pharmaceutical distributors and pharmacies such as CVS Health, Cardinal Health, Chartwell and USADA using its reusable shipping solutions.

What awards have Ember’s cold chain products, including Ember Cube 2, received?

Ember Cube 2 received a Red Dot “Best of the Best” product design award. According to Ember LifeSciences, the original Ember Cube was named a 2024 TIME Invention of the Year and a 2024 Fast Company World Changing Idea.

How does Ember LifeSciences aim to address pharmaceutical cold chain losses?

Ember LifeSciences targets losses from temperature excursions in pharmaceutical distribution using reusable shipping platforms. According to Ember LifeSciences, Ember Cube and Ember Cube 2 combine precise temperature control, real-time monitoring and cloud tracking to improve cold chain reliability as more medicines require temperature-controlled logistics.